Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Inclusion Criteria: * Subjects must have histologicallyor cytologically confirmed diagnosis of pancreatic adenocarcinomaor adenosquamous carcinoma. * Subjects must have resectable right-sided (head/neck/uncinate) pancreatic cancer based on CT or MRI imaging (pancreas protocol CT of the abdomen and pelvis if possible, MRI with contrast or CT with IV contrast in the absence of a pancreas protocol CT scan, CT of the chest with or without contrast) as determined by the PI or Co-investigators. Participants with contrast allergies may be permitted without contrastscans if approved by the PI or Co-Investigators for safety reasons. * Male or female subjects age \>18 years of age. * Eastern Cooperative Oncology Group (ECOG) Performance status being 0-1 within 2 weeks of planned start of therapy. * Subjects must have normal organ and marrow function as defined below within 2 weeks of C1D1: * Adequate hematologic (white blood cell \[WBC\] ≥ 3500 cells/mm3; platelet count ≥100,000 cells/mm3; absolute neutrophil count \[ANC\] ≥1500 cells/mm3; and hemoglobin ≥8 g/dL). * Adequate hepatic function (aspartate aminotransferase \[AST/SGOT\] \<3x upper normal limit \[UNL\], alanine aminotransferase \[ALT/SGPT\] \<3x UNL, bilirubin \<3x UNL). * Adequate renal function (serum creatinine \<2.0 mg/dL or 177 μmol/L). * Adequate coagulation ("International Normalized Ratio" or INR must be \<1.5) unless on therapeutic blood thinners. * Screening HgbA1C \< 7.0% * Expected survival ≥3 months in the view…